Summary:

- The article discusses a new gene therapy approach developed by researchers at Harvard and MIT that has shown promise in treating Huntington's disease, a devastating genetic disorder that causes involuntary movements and cognitive decline.

- The therapy involves delivering a gene-editing tool called CRISPR-Cas9 to target and disable the mutant huntingtin gene, which is responsible for the development of Huntington's disease.

- Preliminary results from animal studies and early-stage human trials have demonstrated the therapy's ability to reduce the levels of the mutant huntingtin protein and improve motor function, offering hope for a potential treatment for this currently incurable condition.